Evidence map›Paper›PMID 42436312›Full record

ArticleTherapeutic innovation & regulatory science2026

Two Decades of Progress and Remaining Challenges: Comparative Analysis of Rare Disease Policy Implementation in Bulgaria, Romania, and Greece.

Iva Nenkova, Petya Pavlikyanova, Adina Turcu-Stiolica, Mihaela-Simona Naidin, Athanasios Margetis, Stanislava Yordanova, Assena Serbezova, Maria Kamusheva

Abstract read
PubMed Publisher
In one paragraph

Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Iva NenkovaDepartment "Organisation and economics of pharmacy", Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria. iva.krasimirovaa@gmail.com.ORCID https://orcid.org/0009-0006-2428-9939
Petya PavlikyanovaDepartment "Organisation and economics of pharmacy", Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria.ORCID http://orcid.org/0009-0008-2992-8423
Adina Turcu-StiolicaDepartment of Pharmaceutical management and marketing, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.ORCID http://orcid.org/0000-0003-1374-276X
Mihaela-Simona NaidinDepartment of Pharmaceutical management and marketing, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.ORCID http://orcid.org/0000-0001-9173-2976
Athanasios MargetisHealth Technology Assessment and Reimbursement Committee, Greek Ministry of Health, Athens, Greece.ORCID http://orcid.org/0009-0004-8680-062X
Stanislava YordanovaCommunity pharmacist, Sofia, Bulgaria.ORCID http://orcid.org/0000-0003-4856-3665
Assena SerbezovaFaculty of Public Health, Medical University-Sofia, Sofia, Bulgaria.ORCID http://orcid.org/0000-0002-1949-1212
Maria KamushevaDepartment "Organisation and economics of pharmacy", Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria.ORCID http://orcid.org/0000-0002-4379-5283

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRare diseases (RDs) pose significant challenges to public health, affecting millions of individuals across the world. Since the adoption of Regulation (EC) No. 141/2000, the European Union (EU) has provided a unified framework for national RD policies. This study provides an overview of RDs legislation over the past two decades (2000-2024), with a comparative analysis of the period 2012-2024 in three neighbouring EU Member States: Bulgaria, Romania, and Greece. The analysis focuses on legal frameworks, national strategies, centres of expertise (CEs), and disease registries.

resultsAll three countries have developed RD-related policy structures aligned with EU standards; however, important differences remain in their level of institutionalisation, coordination, and implementation. Bulgaria demonstrates a more formalised organisational framework through the early adoption of a dedicated National Rare Disease Programme (NRDP), an official RD list, and formal coordination mechanisms, alongside the expansion of CEs, disease registries, and neonatal screening. In contrast, Romania and Greece lack updated standalone NRDPs, with Romania integrating RD policies within broader national health strategies and Greece relying more on fragmented initiatives and broader healthcare reforms. While CEs, registries, and neonatal screening programmes are present across all three countries, differences persist in their organisation, national coordination, and degree of integration. Overall, the existence of policy frameworks and organisational structures does not necessarily indicate their effective implementation, integration, or equitable patient access.

conclusionsRD policy frameworks in Bulgaria, Romania, and Greece have developed over the past two decades, reflecting progressive alignment with EU-level recommendations. However, implementation remains uneven, fragmented, and differently organised across the three countries. These findings suggest that legislative harmonisation alone is insufficient to ensure coordinated and effective RD policy implementation. Future research is needed to examine how these structures function in practice and whether they improve healthcare delivery, care coordination, and patient outcomes.

Indexed as

Balkan regionEuropean UnionHealthcare policyLegislationOrphan medicinal productsRare diseases

Identifiers

PMID42436312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.